An Open-Label, Rater-Blinded, 8-Week Trial of Bupropion Hydrochloride Extended-Release in Patients with Major Depressive Disorder with Atypical Features
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seo, H. -J. | - |
dc.contributor.author | Lee, B. C. | - |
dc.contributor.author | Seok, J. -H. | - |
dc.contributor.author | Jeon, H. J. | - |
dc.contributor.author | Paik, J. -W. | - |
dc.contributor.author | Kim, W. | - |
dc.contributor.author | Kwak, K. -P. | - |
dc.contributor.author | Han, C. | - |
dc.contributor.author | Lee, K. -U. | - |
dc.contributor.author | Pae, C. -U. | - |
dc.date.accessioned | 2021-09-05T22:01:36Z | - |
dc.date.available | 2021-09-05T22:01:36Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2013-09 | - |
dc.identifier.issn | 0176-3679 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/102237 | - |
dc.description.abstract | Objectives: The present study aimed at investigating the effectiveness and tolerability of -bupropion hydrochloride extended release (XL) in major depressive disorder (MDD) patients with atypical features (AF). Methods: 51 patients were prescribed bupropion XL for 8 weeks (6 visits: screening, baseline, weeks 1, 2, 4 and 8). The primary efficacy measure was a change of the Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version (SIGH-SAD) from baseline to endpoint. Secondary efficacy measures included the SIGH-SAD atypical symptoms subscale, Clinical Global Impression-Severity (CGI-S), Sheehan Disability Scale (SDS) and Epworth Sleepiness Questionnaire (ESQ). Response or remission was defined as >= 50% reduction or <= 7 in SIGH-SAD total scores, respectively, at end of treatment. Results: The HAM-D-29 total score reduced by 55.3% from baseline (27.3 +/- 6.5) to end of treatment (12.2 +/- 6.3) (p<0.001). Atypical symptom subscale scores also reduced by 54.5% from baseline (9.2 +/- 3.0) to end of treatment (4.2 +/- 2.8) (p<0.001). At the end of treatment, 24.4% (n=10) and 51.2% (n=21) subjects were classified as remitters and responders, respectively. The most frequently reported AEs were headache (13.7%), dry mouth (11.8%), dizziness (9.8%), and dyspepsia (9.8%). Conclusions: Our preliminary study indicates that bupropion XL may be beneficial in the treatment of MDD with atypical features. Adequately powered, randomized, double-blind, placebo-controlled trials are necessary to determine our results. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | GEORG THIEME VERLAG KG | - |
dc.subject | ANTIDEPRESSANT EFFICACY | - |
dc.subject | IMIPRAMINE | - |
dc.subject | FLUOXETINE | - |
dc.subject | PHENELZINE | - |
dc.subject | VALIDATION | - |
dc.subject | DOPAMINE | - |
dc.subject | MOCLOBEMIDE | - |
dc.subject | VENLAFAXINE | - |
dc.subject | SLEEPINESS | - |
dc.subject | SEROTONIN | - |
dc.title | An Open-Label, Rater-Blinded, 8-Week Trial of Bupropion Hydrochloride Extended-Release in Patients with Major Depressive Disorder with Atypical Features | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Han, C. | - |
dc.identifier.doi | 10.1055/s-0033-1353171 | - |
dc.identifier.scopusid | 2-s2.0-84884280416 | - |
dc.identifier.wosid | 000324401000004 | - |
dc.identifier.bibliographicCitation | PHARMACOPSYCHIATRY, v.46, no.6, pp.221 - 226 | - |
dc.relation.isPartOf | PHARMACOPSYCHIATRY | - |
dc.citation.title | PHARMACOPSYCHIATRY | - |
dc.citation.volume | 46 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 221 | - |
dc.citation.endPage | 226 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | ANTIDEPRESSANT EFFICACY | - |
dc.subject.keywordPlus | IMIPRAMINE | - |
dc.subject.keywordPlus | FLUOXETINE | - |
dc.subject.keywordPlus | PHENELZINE | - |
dc.subject.keywordPlus | VALIDATION | - |
dc.subject.keywordPlus | DOPAMINE | - |
dc.subject.keywordPlus | MOCLOBEMIDE | - |
dc.subject.keywordPlus | VENLAFAXINE | - |
dc.subject.keywordPlus | SLEEPINESS | - |
dc.subject.keywordPlus | SEROTONIN | - |
dc.subject.keywordAuthor | response | - |
dc.subject.keywordAuthor | remission | - |
dc.subject.keywordAuthor | effectiveness | - |
dc.subject.keywordAuthor | tolerability | - |
dc.subject.keywordAuthor | atypical depression | - |
dc.subject.keywordAuthor | bupropion XL | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.